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Abstract
          Neutropenia, secondary to immune destruction or maturation 
arrest, is the most commonly described adverse haematological ef-
fect of beta-lactam antibiotics. We describe a case of reversible pan-
cytopenia, with evidence of hypocellular marrow, after a prolonged 
course of piperacillin/tazobactam for 26 days.
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Introduction
  Piperacillin/tazobactam  is  a  semisynthetic  ureidope-
nicillin and a beta-lactamase inhibitor, with broad-spectrum 
and  increased  activity  against  Pseudomonas  aeruginosa 
when compared with other penicillins. Bone marrow sup-
pression is a recognized adverse drug reaction of beta-lactam 
antibiotics. A recent systematic review have supported the 
assumption that piperacillin can also have such adverse ef-
fects [1]. We report a case of reversible bone marrow toxic-
ity associated with piperacillin/tazobactam use. This report 
reinforces previous suggestions that monitoring of haemato-
logical parameters is crucial in patients receiving prolonged 
treatment with piperacillin.
 
Case report
  A 60-year-old man with a history of failed renal trans-
plant on peritoneal dialysis was admitted for parainfluenza 
infection. He had a recent history of video-assisted thoraco-
scopic surgery with pleurodesis for right pleural effusion four 
months ago. On admission, he was noted to have a tempera-
ture of 38oC and a right chest wall abscess over the previous 
surgical site. Computed tomography of the thorax showed 
loculated pleural collections and subsequent culture of pleu-
ral aspirate grew Pseudomonas aeruginosa. The patient was 
started on piperacillin/tazobactam (2/0.25 g every 8 hours) 
and gentamicin. Complete blood count at baseline showed 
chronic hypochromic normocytic anemia (haemoglobin 89 
g/L), platelet count 232 x 109/L and white cell count 10.5 
x 109/L. After 23 days of antimicrobial therapy, our patient 
developed thrombocytopenia of 128 x 109/L, whilst haemo-
globin level decreased to 77 g/L. On day 26 of treatment, his 
platelet count was further reduced to 90 x 109/L. Both piper-
acillin/tazobactam and gentamicin was stopped after 30 days 
of  piperacillin/tazobactam  treatment,  in  view  of  possible 
bone marrow toxicity. Two days after stopping the antibiotic, 
haemoglobin level measured 55 g/L, and the platelet count 
9 x 109/L. The lowest haemoglobin level and platelet count 
were 43 g/L and 2 x 109/L respectively (Fig. 1); transfusion 
support was given. Bone marrow examination (Fig. 2) then 
demonstrated a hypocellular marrow characterized by mark-
edly reduced erythropoiesis and megakaryopoiesis, without 
abnormal infiltration. Parvovirus B19-specific IgM antibody 
and polymerase chain reaction assay were both negative.
  His  haemoglobin  level  and  platelet  count  recovered 
after  stopping  piperacillin/tazobactam.  His  empyema  was 
subsequently treated with cefoperazon/sulbactam and gen-
tamicin for another three weeks, with no further cytopenia 
observed.
  
Discussion
  
  Reversible myelosuppression has been reported as an 
uncommon adverse reaction of piperacillin. Like other beta-
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lactams, neutropenia is the most common abnormality, and 
is often associated with mild thrombocytopenia. Thrombo-
cytopenia rarely occurs alone, and isolated anaemia has not 
been described before. 
  The mechanism by which marrow toxicity develops re-
mains speculative. It is believed that piperacillin causes pro-
liferation arrest of the myeloid cells. Only one case report of 
piperacillin/tazobactam related pancytopenia had been docu-
mented by bone marrow aspiration [2], which demonstrated 
a rich marrow with maturation arrest of all lineages. More-
over, published studies have also detected immunologically-
mediated haemolytic anaemia and thrombocytopenia [1], in 
the presence of IgG antibodies against penicillins. Despite 
recent  attention  in  the  adverse  haematological  effects  of 
piperacillin, current understanding is by and large derived 
from sporadic case reports pertaining to leucopenia [3-5], 
anaemia or thrombocytopenia [5-8].
   More large-scale cohort studies suggested that the my-
elotoxicity is related to large cumulative doses. The adverse 
haematological  reaction  rarely  occurs  with  treatment  less 
than 10 days, although a study of 41 patients receiving piper-
acillin/tazobactam  for  bone-related  infections  showed  no 
significant difference between the mean treatment duration 
of neutropenic and non-neutropenic patients [3]. The same 
study demonstrated a significantly younger mean age for the 
group with neutropenia. Younger patients, especially chil-
dren, tend to be more vulnerable. Of the three published case 
reports regarding this topic, the patients were between the 
ages of 18 to 27 years [2, 6, 7]. In a case series of 25 patients, 
including five subjects under the age of 18, piperacillin was 
used  to  treat  Pseudomonas  infection.  Six  patients  subse-
quently developed neutropenia, of which four were children 
[5]. Children appear to develop haematological toxicity with 
a shorter duration of piperacillin therapy when compared to 
adults. One case report has suggested that this effect may be 
related to body weight [2], and recommends a dosage reduc-
tion in underweight patients.
  Although piperacillin/tazobactam is eliminated in the 
Figure 1. Trend of (a) platelet count and  (b) haemoglobin concentration in relation to piperacillin/tazobactam administration.
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urine, patients with renal insufficiency receiving dose-ad-
justed piperacillin/tazobactam therapy have not been report-
ed to be at increased risk of myelotoxicity. Nevertheless, the 
delayed recovery of pancytopenia in our patient may well be 
explained by underlying renal failure, as well as the presence 
of hypocellular marrow, both of which have been found to be 
adverse prognostic factors for recovery in toxic neutropenia 
[9]. The true incidence of piperacillin bone marrow suppres-
sion is hitherto unknown, and may be explained by a pau-
city of data involving more than two weeks of piperacillin/
tazobactam therapy. Much less is known about the genetic 
predisposition  to  this  haematological  adverse  reaction  of 
piperacillin/tazobactam. Further studies will also be critical 
in determining whether and, if so, which signal heralds the 
development of bone marrow suppression after piperacillin/
tazobactam.
 The key points from this case are: Piperacillin/tazo-
bactam treatment, if prolonged, can be associated with bone 
marrow  suppression;  Besides  the  oft-quoted  neutropenia, 
other manifestation includes thrombocytopenia and/or pan-
cytopenia; Vigilance by clinicians in detecting and diagnos-
ing this reversible adverse drug reaction is important. Early 
recognition should probably be achieved by regular monitor-
ing of blood counts in patients receiving more than 10 days 
of piperacillin/tazobactam.
  In conclusion, cytopenia involving any of the myeloid 
lineages may occur with prolonged piperacillin/tazobactam 
treatment. It would be wise to recommend, pending further 
evidence on this haematological adverse reaction of piper-
acillin, regular monitoring of blood counts in patients receiv-
ing more than 10 days of therapy.
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Figure 2. (a) Very hypocellular marrow aspirate at low power view; (b) Cellular area from the hypocellular bone marrow aspirate 
showing granulopoiesis with markedly reduced erythropoiesis.
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